Coronavirus pandemic has emerged as an extraordinary healthcare crisis in modern times.
The SARS-CoV-2 novel coronavirus has high transmission rate, is more aggressive and
virulent in comparison to previously known coronaviruses. It primarily attacks the
respiratory system by inducing cytokine storm that causes systemic inflammation and
pulmonary fibrosis. Decorin is a pluripotent molecule belonging to a leucine rich
proteoglycan group that exerts critical role in extracellular matrix (ECM) assembly
and regulates cell growth, adhesion, proliferation, inflammation, and fibrogenesis.
Interestingly, decorin has potent anti-inflammatory, cytokine inhibitory, and anti-fibrillogenesis
effects which make it a potential drug candidate against the COVID-19 related complications
especially in the context of lung fibrosis. Herein, we postulate that owing to its
distinctive pharmacological actions and immunomodulatory effect, decorin can be a
promising preclinical therapeutic agent for the therapy of COVID-19.